Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ELTROMBOPAG OLAMINE

All products: not a benefit

Revolade · DIN 02361833 · 50mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Revolade · DIN 02361833 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2023-07-31 Health Canada: Marketed since 2016-02-16 · brand REVOLADE · ATC B02BX05 ELTROMBOPAG · form Tablet · route Oral · ingredients ELTROMBOPAG (ELTROMBOPAG OLAMINE) 50 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $110.5000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84688 · Verify on the e-Formulary ↗ (DIN 02361833)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02361833). DIN 02361833: Revolade Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 201600050; group id 267; item number 0540; lccId None; manufacturer id GSK Source form: Tab; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $130.0000; ministry $110.5000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02361833 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84688
Interchangeable products
Apo-Eltrombopag · DIN 02506769 · $110.5000
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02361833
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (20:16 Hematopoietic Agents) and how they are covered

Matched class: 20:16 Hematopoietic Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: FILGRASTIM, PEGFILGRASTIM 20:16 Hematopoietic Agents

FILGRASTIM

· 10 products · General benefit · strengths: 300mcg/0.5mL, 480mcg/0.8mL, 480mcg/1.6mL, 300mcg/mL · Inj Sol-0.5mL Pref Syr, Inj Sol-0.5mL Pref Syr (Preservative-Free), Inj Sol-0.8mL Pref Syr, Inj Sol-0.8mL Pref Syr (Preservative-Free), Inj Sol-1.6mL Vial Pk, Inj Sol-1mL Vial Pk, Pref Syr-0.5mL Pk, Pref Syr-0.8mL Pk

PEGFILGRASTIM

· 7 products · General benefit · strengths: 6mg/0.6mL, 10mg/mL · Inj Sol-0.6mL Pref Autoinj (Preservative-Free), Inj Sol-0.6mL Pref Syr (Preservative-Free), Inj Sol-0.6mL Pref Syr Pk (Preservative-Free), Inj Sol-Pref Syr, Inj Sol-Pref Syr - 0.6mL Pk (Preservative Free)

DARBEPOETIN ALFA

· 4 products · Limited Use, codes 420 · strengths: 150mcg/0.3mL, 200mcg/0.4mL, 300mcg/0.6mL, 500mcg/1.0mL · Pref Syr-0.3mL Pk, Pref Syr-0.4mL Pk, Pref Syr-0.6mL Pk, Pref Syr-1.0mL Pk

EPOETIN ALFA

· 3 products · Limited Use, codes 420 · strengths: 10,000IU/mL, 40,000IU/mL, 20,000IU/0.5mL · Pref Syr - 1mL Pk, Pref Syr-0.5mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 20:16
Full class listing Related classes: 20:04 Antianemia Drugs, 20:12 Coagulants and Anti-Coagulants, 20:24 Hemorrheologic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. INDICATIONS  REVOLADE (eltrombopag) tablets are indicated for the treatment of chronic immune thrombocytopenia (ITP) to increase platelet counts in adult and pediatric patients one year and older who have had an insufficient response to corticosteroids or immunoglobuli ns.  REVOLADE is indicated to increase platelet counts in thrombocytopenic patients with chronic hepatitis C virus (HCV) infection to allow the initiation and maintenance of interferon -based therapy.  REVOLADE is indicated for the treatment of adult patients with severe aplastic anemia (SAA) who have had an insufficient response to immunosuppressive therapy. 1.1 Pediatrics Pediatrics (< 18 years): The safety and efficacy of REVOLADE have not been established in pediatric ITP patients younger than 1 year. In pediatric ITP patients one year and older the long- term safety and efficacy of REVOLADE have not been studied. The safety and efficacy of REVOLADE in pediatric patients with chronic HCV or SAA have not been established. 1.2 Geriatrics Geriatrics (≥ 65 years of age): Clinical studies of REVOLADE did not include sufficient numbers of patients aged 65… https://pdf.hres.ca/dpd_pm/00063465.PDF PM date: Nov 03, 2021 Source product: REVOLADE; DIN 02361825; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Revolade: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026